跳至主要内容
临床试验/EUCTR2005-001705-26-DE
EUCTR2005-001705-26-DE进行中(未招募)不适用

Efficacy and safety of topically applied cyclodextrin gel (Spirig Pharma) in the treatment of recurrent genital herpes simplex virus infections: a randomised, double-blind, placebo-controlled, multicentre trial. - NA

Spirig Pharma AG0 个研究点目标入组 200 人开始时间: 2005年10月18日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
200

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Medically confirmed diagnosis of recurrent genital herpes (Herpes simplex)
  • Diameter of lesion < 3 mm,
  • History of 4 to 10 relapses of genital herpes within one year prior to inclusion in the study.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Malignant diseases,
  • Diabetes mellitus type 1,
  • Clinically relevant renal impairment,
  • Concomitant therapy with immunosuppressive drugs,
  • Systemic antiviral therapy within 7 days prior to randomisation and during this study.

研究者

相似试验